Clinical Trials Browser

Phase 1/2 × Blastic Plasmacytoid Dendritic Cell Neoplasm × Clear all

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03386513 2024-12-16

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Phase 1/2 Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Disorders, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

138 enrolled 23 charts 2 FDA

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT04109482 2024-07-22

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Phase 1/2 Terminated

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06006403 2023-08-30

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute

NCT00397579 2019-04-23

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 1/2 Completed

11 enrolled 6 charts

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute